1,1-dimethylethyl 3-(3-chlorobenzoyl)-1-piperidinecarboxylate | 912769-44-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,1-dimethylethyl 3-(3-chlorobenzoyl)-1-piperidinecarboxylate
• 英文别名: (R)-tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate；Tert-butyl 3-(3-chlorobenzoyl)piperidine-1-carboxylate
• CAS: 912769-44-9
• 化学式: C₁₇H₂₂ClNO₃
• 分子量: 323.82
• InChiKey: BAGDSBRGWXVOOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 3-(3-chlorobenzoyl)-1-piperidinecarboxylate 在 C₅₄H₄₈Cl₂N₂P₂Ru 、 potassium tert-butylate 、 氢气 作用下， 以 异丙醇 为溶剂， 25.0 ℃ 、1.01 MPa 条件下， 反应 20.0h， 以99%的产率得到1,1-dimethylethyl (3S)-3-[(S)-(3-chlorophenyl)hydroxymethyl]-1-piperidinecarboxylate
  参考文献：
  名称：

  杂环烷基酮加氢中催化剂控制的非对映异构

  摘要：

  在反应位点附近具有小的空间和电子差异的α-取代的手性酮是难以以高非对映选择性还原的底物。使用硼氢化钠，硼氢化锌和三仲丁基硼氢化钾作为还原剂，对2-（4-苯甲酰基吗啉基）苯基酮和3-（1-叔丁氧基羰基哌啶基）苯基酮进行金属氢化物还原，可制得顺式和反式醇比例低于80:20。这些酮用的RuCl的催化剂体系的加氢2（BIPHEP）（DMEN）和氢叔在2-丙醇结果丁醇顺选择性≥99：1的醇[BIPHEP = 2,2'-双（二苯基膦基）联苯，DMEN = N，N-二甲基乙二胺]。非对映选择性的显着差异表明该氢化反应中的立体选择主要由催化剂反应场的结构（“催化剂控制的非对映选择性”）调节，而不是由底物的内部立体控制。该化学是通过动态动力学拆分用的RuCl施加到不对称氢化2 - [（小号）-BINAP] [（[R）-DMAPEN] /钾叔-丁氧化物催化剂[BINAP = 2,2'-双（二苯基膦基）-1,1'-联萘基，DMAPEN

  DOI：

  10.1002/adsc.201100398

文献信息

• RENIN INHIBITORS
  申请人：Baldwin John J.

  公开号：US20100184805A1

  公开（公告）日：2010-07-22

  Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also directed to pharmaceutical compositions comprising a compound described herein or enantiomers, diastereomers, or salts thereof and a pharmaceutically acceptable carrier or excipient.

  揭示了以下结构式所代表的天冬氨酸蛋白酶抑制剂，以及其药学上可接受的盐。这些化合物可经口给药，并结合到天冬氨酸蛋白酶上以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性有关的疾病方面具有用途。本发明还涉及包括本文所述化合物或其对映体、二对映体或盐以及药学上可接受的载体或赋形剂的制药组合物。
• Piperidine derivatives as renin inhibitors
  申请人：Baldwin John J.

  公开号：US20090318501A1

  公开（公告）日：2009-12-24

  The present invention is directed to aspartic protease inhibitors represented by the following structural formula; or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.

  本发明涉及以下结构式所表示的天冬氨酸蛋白酶抑制剂; 或其药学上可接受的盐。本发明还涉及包括结构式（I）的天冬氨酸蛋白酶抑制剂的制药组合物。本发明还揭示了在需要拮抗一种或多种天冬氨酸蛋白酶的主体中拮抗一种或多种天冬氨酸蛋白酶的方法，以及使用这些天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• Diaminoalkane Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20090018103A1

  公开（公告）日：2009-01-15

  Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.

  公式I的Diaminoalkanes现已被发现，它们具有口服活性并结合到天冬氨酸蛋白酶以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性升高相关的疾病方面非常有用。本发明还涉及使用公式I化合物治疗或改善需要的天冬氨酸蛋白酶相关疾病的方法，包括向该受体施用公式I化合物的有效量。
• Piperidine and Morpholine Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264432A1

  公开（公告）日：2009-10-22

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服的化合物，它们能够结合到肾素并抑制其活性。它们在治疗或改善与肾素活性相关的疾病方面是有用的。同时描述了使用这些化合物治疗或改善受肾素介导的疾病的方法。
• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。